Conference Call with IOL Chemicals and Pharmaceuticals Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
IOL Chemicals and Pharmaceuticals announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Total income at Rs 511 crore against Rs 596 crore EBITDA at Rs 57.6 crore against Rs 104.5 crore Net profit at Rs 28.2 crore against Rs 65.3 crore FY24 Financial Highlights: Total income at Rs 2,162.9 crore against Rs 2,242.7 crore EBITDA up 3.8% YoY to Rs 261.6 crore Net profit at Rs 135 crore against Rs 140 crore Commenting on the performance, Vikas Gupta, Joint Managing Director said, “The Company has exhibited resilient financial performance in FY24 despite challenging macro-economic environment and volatile chemical sector trajectory. We are receiving positive response in export market despite geopolitical uncertainties and supply chain obstacles. Though, the revenue growth has been sluggish, the margins were stable following Company’s sustained cost control initiatives. We believe that chemical sector turbulence would likely stabilize this financial year. In the nonIbuprofen segment, we are on track to expand our footprints in key regulated markets following approvals and certifications received last year. During the year the capex in infrastructure and automization will improve the operational efficiency and reduce the carbon footprint.” Result PDF
IOL Chemicals and Pharmaceuticals announced Q1FY24 results: Total income for Q1FY24 stood at Rs 570 crore at the same level of Rs 570 crore in Q1FY23 EBITDA for Q1FY24 at Rs 80 crore as compared to Rs 61 crore in Q1FY23 Net profit for Q1FY24 at Rs 46 crore as compared to Rs 35 crore in Q1FY23 Commenting on the performance, Vikas Gupta, Joint Managing Director, said, “We are pleased to report sustainable performance during Q1FY24, tackling present challenges while positioning ourselves for forthcoming opportunities. We are hopeful for an increased presence in regulatory markets as the Company got CEP for paracetamol. Additionally, with the commencement of the Acetic Anhydride plant, focus on improved efficiencies, product mix, and timely execution we are hopeful to generate strong cash flow”. Result PDF
Conference Call with IOL Chemicals and Pharmaceuticals Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.